All Stories

Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.

Mar 13, 2025 - 23:23
 0
Sotio takes up option on ADCs, while Boehringer inks GPCR discovery pact
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates, taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same day as Salipro Biotech revealed a partnership with Boehringer Ingelheim.
Read More

Tags:

Previous Article

Hologen AI commits up to $430M to help take MeiraGTx's Parkinson's gene therapy ...

Next Article

ImmunoPrecise teases $10M ADC, bispecific collab with major biotech

Related Posts

GSK plans to move vaccine R&D center from Rockville, Maryland to the Boston area

GSK plans to move vaccine R&D center from Rockville, Ma...

Feb 12, 2025  0

Illumina aims to cut $100M in costs following China import ban

Illumina aims to cut $100M in costs following China imp...

Mar 11, 2025  0

FDA approves Medtronic’s adaptive deep-brain stimulator for Parkinson’s disease

FDA approves Medtronic’s adaptive deep-brain stimulator...

Feb 24, 2025  0